^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:MyProstateScore 2.0
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Lynx DxType:
Laboratory Developed Test
MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer (Gleason score ≥7 or Grade Group ≥2) by analyzing a comprehensive array of 18 unique gene transcripts. Among the transcripts is the novel gene fusion, T2:ERG. The MPS2 algorithm has been developed to optimize diagnostic accuracy and provide clinical flexibility. MPS2 can be run as a biomarker-only test or inclusive of clinical risk factors, depending on provider preference.
Cancer:
Prostate Cancer
Gene:
APOC1 (Apolipoprotein C1), B3GNT6 (UDP-GlcNAc:BetaGal Beta-1,3-N-Acetylglucosaminyltransferase 6), CAMKK2 (Calcium/Calmodulin Dependent Protein Kinase Kinase 2), ERG (ETS Transcription Factor ERG), HOXC6 (Homeobox C6), KLK3 (Kallikrein-related peptidase 3)
See More ...
APOC1 (Apolipoprotein C1), B3GNT6 (UDP-GlcNAc:BetaGal Beta-1,3-N-Acetylglucosaminyltransferase 6), CAMKK2 (Calcium/Calmodulin Dependent Protein Kinase Kinase 2), ERG (ETS Transcription Factor ERG), HOXC6 (Homeobox C6), KLK3 (Kallikrein-related peptidase 3), KLK4 (Kallikrein Related Peptidase 4), NKAIN1 (Sodium/Potassium Transporting ATPase Interacting 1), OR51E2 (Olfactory Receptor Family 51 Subfamily E Member 2), PCA3 (Prostate cancer associated 3), PCAT14 (Prostate Cancer Associated Transcript 14), PCGEM1 (PCGEM1 Prostate-Specific Transcript), SCHLAP1 (SWI/SNF Complex Antagonist Associated With Prostate Cancer 1), SPON2 (Spondin 2), TFF3 (Trefoil factor 3), TMSB15A (Thymosin Beta 15A), TRGV9 (T Cell Receptor Gamma Variable 9)
Method:
Next-Generation Sequencing (NGS)
